vs
Side-by-side financial comparison of Aclaris Therapeutics, Inc. (ACRS) and PMV Pharmaceuticals, Inc. (PMVP). Click either name above to swap in a different company.
Aclaris Therapeutics, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.2M, roughly 1.1× PMV Pharmaceuticals, Inc.). On growth, PMV Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-46.1% vs -85.9%). PMV Pharmaceuticals, Inc. produced more free cash flow last quarter ($-17.2M vs $-47.2M). Over the past eight quarters, Aclaris Therapeutics, Inc.'s revenue compounded faster (-26.5% CAGR vs -35.4%).
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies targeting mutations in the p53 tumor suppressor gene, one of the most frequently altered genes in human cancers. Its lead product candidates address unmet medical needs for patients with hard-to-treat solid and hematologic malignancies, serving global oncology patient segments.
ACRS vs PMVP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.2M |
| Net Profit | — | $-18.0M |
| Gross Margin | 58.9% | — |
| Operating Margin | — | -1561.8% |
| Net Margin | — | -1464.0% |
| Revenue YoY | -85.9% | -46.1% |
| Net Profit YoY | 79.5% | 21.6% |
| EPS (diluted) | — | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $1.2M | ||
| Q3 25 | $3.3M | $1.5M | ||
| Q2 25 | $1.8M | $1.7M | ||
| Q1 25 | $1.5M | $1.9M | ||
| Q4 24 | $9.2M | $2.3M | ||
| Q3 24 | $4.3M | $2.6M | ||
| Q2 24 | $2.8M | $2.8M | ||
| Q1 24 | $2.4M | $3.0M |
| Q4 25 | — | $-18.0M | ||
| Q3 25 | $-14.6M | $-21.1M | ||
| Q2 25 | $-15.4M | $-21.2M | ||
| Q1 25 | $-15.1M | $-17.4M | ||
| Q4 24 | $-96.6M | $-23.0M | ||
| Q3 24 | $-7.6M | $-19.2M | ||
| Q2 24 | $-11.0M | $-1.2M | ||
| Q1 24 | $-16.9M | $-15.3M |
| Q4 25 | 58.9% | — | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 71.0% | — | ||
| Q1 25 | 65.2% | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 66.3% | — |
| Q4 25 | — | -1561.8% | ||
| Q3 25 | -519.8% | -1521.8% | ||
| Q2 25 | -1035.9% | -1353.8% | ||
| Q1 25 | -1242.9% | -1114.4% | ||
| Q4 24 | -1082.3% | -1100.5% | ||
| Q3 24 | -240.9% | -837.0% | ||
| Q2 24 | -464.7% | -720.1% | ||
| Q1 24 | -789.4% | -617.2% |
| Q4 25 | — | -1464.0% | ||
| Q3 25 | -443.0% | -1422.9% | ||
| Q2 25 | -868.3% | -1255.0% | ||
| Q1 25 | -1036.8% | -901.1% | ||
| Q4 24 | -1048.3% | -1005.7% | ||
| Q3 24 | -174.6% | -735.2% | ||
| Q2 24 | -397.2% | -43.3% | ||
| Q1 24 | -706.5% | -517.3% |
| Q4 25 | — | $-0.33 | ||
| Q3 25 | $-0.12 | $-0.40 | ||
| Q2 25 | $-0.13 | $-0.41 | ||
| Q1 25 | $-0.12 | $-0.34 | ||
| Q4 24 | $-1.21 | $-0.45 | ||
| Q3 24 | $-0.11 | $-0.37 | ||
| Q2 24 | $-0.15 | $-0.02 | ||
| Q1 24 | $-0.24 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $112.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $103.1M | $104.7M |
| Total Assets | $160.5M | $116.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.0M | $112.9M | ||
| Q3 25 | $25.3M | $129.3M | ||
| Q2 25 | $25.4M | $142.3M | ||
| Q1 25 | $30.4M | $160.4M | ||
| Q4 24 | $24.6M | $169.5M | ||
| Q3 24 | $47.7M | $182.8M | ||
| Q2 24 | $22.8M | $212.9M | ||
| Q1 24 | $35.8M | $197.9M |
| Q4 25 | $103.1M | $104.7M | ||
| Q3 25 | $120.1M | $121.0M | ||
| Q2 25 | $131.7M | $140.6M | ||
| Q1 25 | $144.1M | $160.1M | ||
| Q4 24 | $155.6M | $176.1M | ||
| Q3 24 | $130.2M | $197.9M | ||
| Q2 24 | $133.8M | $214.3M | ||
| Q1 24 | $142.0M | $212.7M |
| Q4 25 | $160.5M | $116.6M | ||
| Q3 25 | $175.5M | $133.8M | ||
| Q2 25 | $189.1M | $152.9M | ||
| Q1 25 | $198.1M | $170.6M | ||
| Q4 24 | $220.3M | $191.3M | ||
| Q3 24 | $182.4M | $223.5M | ||
| Q2 24 | $161.1M | $237.5M | ||
| Q1 24 | $174.1M | $236.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.1M | $-17.2M |
| Free Cash FlowOCF − Capex | $-47.2M | $-17.2M |
| FCF MarginFCF / Revenue | -3646.6% | -1396.4% |
| Capex IntensityCapex / Revenue | 8.6% | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-81.3M | $-73.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.1M | $-17.2M | ||
| Q3 25 | $-10.9M | $-19.8M | ||
| Q2 25 | $-10.0M | $-18.3M | ||
| Q1 25 | $-13.1M | $-18.3M | ||
| Q4 24 | $-8.9M | $-16.7M | ||
| Q3 24 | $22.0M | $-16.8M | ||
| Q2 24 | $-12.3M | $-1.6M | ||
| Q1 24 | $-20.8M | $-16.2M |
| Q4 25 | $-47.2M | $-17.2M | ||
| Q3 25 | $-11.0M | $-19.8M | ||
| Q2 25 | $-10.0M | $-18.3M | ||
| Q1 25 | $-13.1M | $-18.3M | ||
| Q4 24 | — | $-16.7M | ||
| Q3 24 | — | $-16.8M | ||
| Q2 24 | $-12.3M | $-1.6M | ||
| Q1 24 | $-20.9M | $-16.8M |
| Q4 25 | -3646.6% | -1396.4% | ||
| Q3 25 | -332.1% | -1339.3% | ||
| Q2 25 | -563.5% | -1083.6% | ||
| Q1 25 | -900.3% | -944.2% | ||
| Q4 24 | — | -731.0% | ||
| Q3 24 | — | -644.0% | ||
| Q2 24 | -446.0% | -57.2% | ||
| Q1 24 | -873.6% | -568.4% |
| Q4 25 | 8.6% | 1.2% | ||
| Q3 25 | 0.7% | 0.1% | ||
| Q2 25 | 1.2% | 0.7% | ||
| Q1 25 | 3.0% | 0.2% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.5% | 0.1% | ||
| Q1 24 | 5.6% | 20.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
